Pharmacy Times

JANUARY 1, 2025

Lp(a) is a critical risk factor for atherosclerotic cardiovascular disease, but current lipid-lowering therapies are largely ineffective at lowering Lp(a) levels.

55

55

Pharmaceutical Commerce

JANUARY 1, 2025

This bucket of Pharma Commerce coverage is highly powered by digital solutions.

Pharma 52

Pharma 52

PharmaTech

JANUARY 1, 2025

In a discussion on bispecific antibody development, Atul Mohindra, head of Biologics R&D at Lonza, points out the challenges and successes of these molecules as well as the fields future direction from a CDMO perspective.

52

52

PharmExec

JANUARY 1, 2025

In this Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), speaks about exciting developments in fertility treatment that he anticipates in the next few years.

Pharmaceutical 52

Pharmaceutical 52

Advertiser: ZoomInfo

Savvy B2B marketers know that a great account-based marketing (ABM) strategy leads to higher ROI and sustainable growth. In this guide, we’ll cover: What makes for a successful ABM strategy? What are the key elements and capabilities of ABM that can make a real difference? How is AI changing workflows and driving functionality? This Martech Intelligence Report on Enterprise Account-Based Marketing examines the state of ABM in 2024 and what to consider when implementing ABM software.

Marketing

Pharmacy Times

JANUARY 1, 2025

Some outsourcers and pharmacies have capitalized on the shortages, producing compounded versions.

FDA 51

FDA 51

PharmExec

JANUARY 1, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Pharmacy Times

JANUARY 1, 2025

Female adolescents were at an increased risk of experiencing depression and anxiety symptoms compared with males.

44

44

Pharmacy Times

JANUARY 1, 2025

Panelists discuss how elafibranor demonstrated significant efficacy in the ELATIVE trial, which strengthens confidence in its role as a long-term treatment option for patients with primary biliary cholangitis (PBC) who inadequately respond to ursodeoxycholic acid.

Patients 26

Patients 26

Pharmacy Times

JANUARY 1, 2025

Panelists discuss how seladelpar showed remarkable efficacy in the RESPONSE trial, demonstrating significant improvements in alkaline phosphatase levels and other biochemical markers compared with placebo.

26

26